U.S. pharmaceutical giant Eli Lilly and Company announced good news on April 17 that its once-daily oral small molecule GLP-1 receptor agonist. Orforglipron has successfully met the primary endpoints in a key Phase 3 clinical trial. The investigational therapy demonstrated a safety and efficacy profile consistent with currently approved injectable GLP-1 drugs. It marks a … Eli Lilly’s Orforglipron Shows Phase 3 Success: First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.